MannKind Corporation to Hold Investor Conference Call
Jan 4, 2019 2:06:55 GMT -5
diski58, prcgorman2, and 1 more like this
Post by lakon on Jan 4, 2019 2:06:55 GMT -5
Mike does seem more savvy than the old leadership so I expect his timing to be better on the share authorization. The finance guys were likely concerned about ongoing macro effects so raised when they could. You may recall missed opportunities to raise before so it's hard to criticize them getting on top of this before it's too late. Something like this may be said to justify the bad timing.
To be clear, you are only screwing yourself if you are unprepared for dilution. The valuation is still incredibly low if you believe in the potential of Afrezza and Technosphere. If you have the money to keep buying in, then, you can maintain your position, and if not, your position was too big to begin with. Unfortunately, it is a harsh reality.
I'm comfortable with the science and potential. I was ecstatic to see UTHR in agreement, and I said for years how they should partner. Similarly, I said that MNKD+AMPH makes even more sense. Both pride themselves in challenging chemistries. As a supplier AND PARTNER, interesting barter transactions can greatly improve their cost+tax structures. AMPH could get MNKD into China for Afrezza along with future API's, and as a bonus, they could pursue another epinephrine formulation. AMPH just got Primatene Mist going again. Why not expand the franchise to a technosphere dry powder formulation as well as for more indications, like anaphylaxis? AMPH is already in emergency medicine. The FDA still has concerns about their new formulation of PM using HFA, but they approved for OTC. Afrezza should go OTC as insulin becomes a biologic in a few years. AMPH just navigated the OTC waters. Get going NOW. Finally, Mintaka may have great philanthropic goals for Oxytocin, but progress has been very slow. Partner with Pfizer, and get the Viagra for Women in orbit.
I do NOT foresee bankruptcy, but I was not as sure a few years ago. Yet, even then, I did not expect bankruptcy so I kept buying. I may look very stupid NOW, but I'm investing for the future value, not present value. I think I'm in good company with Nate, and honestly, I'm a tech-guy, not biotech. I have time to see this through. I am uncomfortable with the prospect of another reverse split; however, that is mainly because it becomes so easy to dilute like a madman. I will just keep buying unless something significantly changes with their prospects; however, I acknowledge that I do not like being forced to increase my risk just to maintain my share of the company. I consider shorting against the box in these perilous times for a little out-of-order-execution.
To be clear, you are only screwing yourself if you are unprepared for dilution. The valuation is still incredibly low if you believe in the potential of Afrezza and Technosphere. If you have the money to keep buying in, then, you can maintain your position, and if not, your position was too big to begin with. Unfortunately, it is a harsh reality.
I'm comfortable with the science and potential. I was ecstatic to see UTHR in agreement, and I said for years how they should partner. Similarly, I said that MNKD+AMPH makes even more sense. Both pride themselves in challenging chemistries. As a supplier AND PARTNER, interesting barter transactions can greatly improve their cost+tax structures. AMPH could get MNKD into China for Afrezza along with future API's, and as a bonus, they could pursue another epinephrine formulation. AMPH just got Primatene Mist going again. Why not expand the franchise to a technosphere dry powder formulation as well as for more indications, like anaphylaxis? AMPH is already in emergency medicine. The FDA still has concerns about their new formulation of PM using HFA, but they approved for OTC. Afrezza should go OTC as insulin becomes a biologic in a few years. AMPH just navigated the OTC waters. Get going NOW. Finally, Mintaka may have great philanthropic goals for Oxytocin, but progress has been very slow. Partner with Pfizer, and get the Viagra for Women in orbit.
I do NOT foresee bankruptcy, but I was not as sure a few years ago. Yet, even then, I did not expect bankruptcy so I kept buying. I may look very stupid NOW, but I'm investing for the future value, not present value. I think I'm in good company with Nate, and honestly, I'm a tech-guy, not biotech. I have time to see this through. I am uncomfortable with the prospect of another reverse split; however, that is mainly because it becomes so easy to dilute like a madman. I will just keep buying unless something significantly changes with their prospects; however, I acknowledge that I do not like being forced to increase my risk just to maintain my share of the company. I consider shorting against the box in these perilous times for a little out-of-order-execution.
